Exhibit 99.1

CDEX Enhances Protection of Intellectual Property Around Substance Detection and
Validation Technologies


ROCKVILLE, MD - February 16, 2006 - CDEX, Inc. (CEXI.OB), a developer of
innovative technologies for detecting and validating chemical substances,
received a notification of allowance from the U.S. Patent and Trademark Office
for Patent Application Publication Number 20030128804, entitled "System and
Method for Adapting a Software Control in an Operating Environment." The patent
applies to a system and method developed by CDEX for detecting substances--such
as explosives or controlled substances. The technology exposes target substances
to an x-ray energy beam and then analyzes and compares the released fluorescent
energy to a database of unique energy signatures of known substances. CDEX
anticipates issuance of the patent in the spring of 2006.

"Protection of our intellectual property is a key part of our ongoing plan for
growth," said Jim Griffin, president and CEO of CDEX. "We are pleased that the
US Patent office has recognized the uniqueness of our technology."

All current CDEX products, such as the ValiMed(TM) medication validation unit
used by hospitals throughout the U.S., are based on applying the same underlying
photoelectric technology for which the company has, in addition to this recently
announced patent, four additional patentsadditional patents pending. CDEX has
also filed corresponding international applications for each of these.

The CDEX ValiMed System offers clinicians a simple and cost-effective tool to
ensure medication safety by verifying that medications are correctly compounded.
The ValiMed System also validates narcotic returns. ValiMed is sold through the
Baxa Corporation, which serves as the exclusive distributor in the United States
and Canada of ValiMed Impaired Clinician Solution, ValiMed Regulatory Compliance
Solution, and ValiMed Patient Safety Solution.

CDEX core technologies are highly scalable. The company is currently developing
products that incorporate the same patent pending technologies currently
employed in existing CDEX products for other market segments, including:

1. Security and Public Safety - Identification of substances of concern (e.g.,
explosives, illegal drugs, chemical/biological weapons, and the detection of
counterfeit drugs and medications to assist in the protection of the nation's
pharmaceuticals supply); and

2. Healthcare - Validation of substances and quality assurance (e.g., validation
of prescription and compounded medications to provide for patient safety,
detection of the diversion of narcotics and controlled substances returned from
operating room suites to the operating room pharmacy, and detection of
counterfeit drugs and medications); and

3. Brand Protection - Detection of counterfeit or sub-par products for brand
protection (i.e., quality assurance inspection of incoming raw materials,
outgoing final products, and products in the distribution channel).


About CDEX, Inc.
CDEX Inc. is a technology development company with a current focus on developing
and marketing products using chemical detection and validation technologies. At
present, CDEX is devoting its resources to two distinct areas: (i)
identification of substances of concern (e.g., explosives and illegal drugs for
homeland security); and (ii) validation of substances for anti-counterfeiting,
brand protection and quality assurance (e.g., validation of prescription
medication and detection of counterfeit or sub-par products for brand
protection). ValiMed is one line of CDEX products for the healthcare market.
CDEX is headquartered in Rockville, Maryland with its research and development
laboratory in Tucson, Arizona. For more information, visit www.cdex-inc.com and
www.valimed.com.

Any statements made in this press release, which contain information that is not
historical, are essentially forward-looking. Many forward-looking statements can
be identified by the use of words such as "expects," "plans," "may,"
"anticipates," "believes," "should," "intends," "estimates," and other words of
similar meaning. These statements are subject to risks and uncertainties that
cannot be predicted or quantified and, consequently, actual results may differ
materially from those expressed or implied by such forward-looking statements.
Such risks are detailed from time-to-time in filings with the Securities and
Exchange Commission. There is no obligation to publicly update any
forward-looking statements.

###